Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): consultee and commentator comments on the ACD

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Amgen
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Merck Serono
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Roche Products
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Nursing
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Royal College of Pathologists
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): Department of Health

This page was last updated: 24 November 2011